GlassScriptPhysician profile
Milady Mortimer-Oragwu
NPI 1184863797
$3,298.61
in general payments reported to CMS, 2019-2025
22 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $220 · 2023: $379 · 2024: $2,276 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,083 · Food and Beverage: $865 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,083.37 |
| Food and Beverage | $865.19 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $2,083.37 | 2024 | Otosight Middle Ear Scope |
| Exeltis, USA INC. | $173.01 | 2022-2025 | Slynd, Tyblume, Nuvessa |
| Abiomed | $143.61 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $137.14 | 2023 | Breztri, Farxiga |
| Currax Pharmaceuticals LLC | $97.53 | 2022-2023 | Nexletol |
| Glaxosmithkline, LLC. | $92.29 | 2022-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $71.18 | 2021-2024 | Jardiance |
| Dexcom, INC. | $64.21 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $55.49 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $54.98 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $46.09 | 2024-2025 | Rybelsus |
| Novartis Pharmaceuticals Corporation | $41.30 | 2021-2022 | |
| Evoke Pharma, INC. | $39.00 | 2023-2024 | Gimoti |
| Hologic Sales and Service, LLC | $28.42 | 2024 | Aptima |
| Genentech USA, INC. | $28.01 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.28 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.90 | 2021-2022 | |
| Scynexis, INC. | $24.98 | 2022 | |
| Amgen INC. | $18.49 | 2024 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $16.44 | 2024 | Nuzyra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.63 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $15.26 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milady Mortimer-Oragwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.